T. Scott

发表

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

Michael Wall, J. Herbert, Jack H. Simon, 2002, Neurology.

Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial

Manesh R. Patel, Timothy N Murphy, Deepak L. Bhatt, 2022, The Lancet.

IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event

D. Arnold, J. Selhorst, R. Kinkel, 2006, Neurology.

Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies

C. Pozzilli, P. Vermersch, B. Sharrack, 2021, Neurology and Therapy.

A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.

D. Arnold, J. Oger, M. Freedman, 2004, Clinical therapeutics.

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Alexander Parajeles Vindas, P. Kowey, D. Arnold, 2016, Neurology. Clinical practice.

Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial

Michael Wall, D. Barlett, J. Herbert, 2002, Multiple sclerosis.

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy

Jeffrey A. Cohen, S. Cole, D. Arnold, 2002, Multiple sclerosis.

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.

J. Selhorst, C. Kollman, R. Kinkel, 2006, Neurology.